New U.S. Biosimilars Bill Gets Mixed Reviews

A new House bill on biosimilars is drawing mixed reviews from industry. The Generic Pharmaceutical Association (GPhA; Arlington, VA) calls the Pathway for Biologics Act “a step backward” that puts brand company profits before patient needs, but the Biotechnology Industry Organization (BIO; Washington) says the bill is an important step forward toward follow-on biologics. Representatives Anna Eshoo (D., CA) and Joe Barton (R., TX) introduced the bill last month. Eshoo: Pathway to promote innovation. The bill provides 12 years of data exclusivity for...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers